GILD
Gilead Sciences Inc (GILD)
Healthcare • NASDAQ • $131.33-2.04%
- Symbol
- GILD
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Price
- $131.33
- Daily Change
- -2.04%
- Market Cap
- $163.06B
- Trailing P/E
- 17.87
- Forward P/E
- 13.58
- 52W High
- $157.29
- 52W Low
- $96.19
- Analyst Target
- $158.07
- Dividend Yield
- +2.50%
- Beta
- 0.33
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the …
Company websiteResearch GILD on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.